

Johns Hopkins Health Plans **Pharmacy Public Medical Management Drug Policies**	*Policy Number*	MMDP107
	Effective Date	01/15/2025
	Approval Date	07/17/2024
Subject **Haegarda**	*Supersedes Date*	N/A
	Page	1 of 3

This document applies to the following Participating Organizations:

US Family Health Plan

Keywords: Haegarda

Table of Contents	Page Number
I. POLICY	1
II. POLICY CRITERIA	1
III. AUTHORIZATION PERIOD/LIMITATIONS	2
IV. EXCLUSIONS	2
V. RECOMMENDED DOSE	2
VI. CODES	2
VII. REFERENCES	2
VIII. APPROVALS	3

I. POLICY

A. Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) will require prior authorization for medical benefit coverage to ensure appropriate use. The process for initiating a prior authorization request can be found in policy PHARM 20.

II. POLICY CRITERIA

A. Haegarda may be approved for patients who meet the following:
   1. Hereditary angioedema (HAE)
      a. Documentation has been submitted showing all the following:
         I. Haegarda will be used for prevention of hereditary angioedema attacks
         II. Haegarda will not be used in combination with any other medication used for prophylaxis of HAE attacks
         III. Patient has one of the following:
            i. Patient has C1 inhibitor deficiency or dysfunction as confirmed by laboratory testing and meets one of the following:
               A. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test
               B. Normal C1-INH antigenic level and a low C1-INH functional level (functional C1-INH less than 50% or C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test).
            ii. Patient has normal C1 inhibitor as confirmed by laboratory testing and meets one of the following criteria:
               A. Patient has an F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation as confirmed by genetic testing
               B. Patient has a documented family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy (i.e., cetirizine at 40 mg per day or the equivalent) for at least one month

© Copyright 2025 by The Johns Hopkins Health System Corporation and/or The Johns Hopkins University



III. AUTHORIZATION PERIOD/LIMITATIONS

A. Initial approval will be limited to 6 months of therapy

B. Continuation of therapy may be approved in 6-month intervals with documentation showing the patient has had a beneficial response, as evidenced by all of the following:

1. Significant reduction in frequency of attacks (e.g., ≥ 50%) since starting treatment
2. A reduced use of medications to treat acute attacks since starting treatment

IV. EXCLUSIONS

A. Haegarda will not be covered for the following:

1. Any indications or uses that are not FDA-approved, or guideline-supported

V. RECOMMENDED DOSE

Please refer to the FDA-approved prescribing information, or clinical guidelines, for indication-specific dosing details.

VI. CODES

CPT Copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

Note: The following CPT/HCPCS codes are included below for informational purposes. Inclusion or exclusion of a CPT/HCPCS code(s) below does not signify or imply member coverage or provider reimbursement. The member's specific benefit plan determines coverage.

Medication	HCPCS/CPT Code
Injection, c-1 esterase inhibitor (human), (haegarda), 10 units	J0599

VII. REFERENCES

1. Haegarda [prescribing information]. Kankakee, IL: CSL Behring LLC; January 2022.
2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update. Allergy. 2022 Jan 10.
3. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67:147-157.
4. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
5. Busse PJ, Christiansen, SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol: In Practice. 2021 Jan;9(1):132-150.
6. Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012; 33(6):S145-S156.
7. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012; 109:395-402.
8. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69: 602-616.

© Copyright 2025 by The Johns Hopkins Health System Corporation and/or The Johns Hopkins University



9. Bowen T. Hereditary angioedema: beyond international consensus – circa December 2010 – The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy Asthma Clin Immunol. 2011;7(1):1.
10. Bernstein JA. Update on angioedema: Evaluation, diagnosis, and treatment. Allergy and Asthma Proceedings. 2011;32(6):408-412.
11. Longhurst H, Cicardi M. Hereditary angio-edema. Lancet. 2012;379:474-481.
12. Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300-313.
13. Henao MP, Kraschnewski J, Kelbel T, Craig T. Diagnosis and screening of patients with hereditary angioedema in primary care. Therapeutics and Clin Risk Management. 2016; 12: 701-711.
14. Bernstein, J. Severity of Hereditary Angioedema, Prevalence, and Diagnostic Considerations. Am J Med. 2018:24; 292-298.
15. Sharma J, Jindal AK, Banday AZ, et al. Pathophysiology of Hereditary Angioedema (HAE) Beyond the SERPING1 Gene. Clin Rev Allergy Immunol. 2021;10.
16. Kanani, A., Schellenberg, R. & Warrington, R. Urticaria and angioedema. All Asth Clin Immun 7, S9 (2011), Table 2.

VIII. APPROVALS

Signature on file at JHHP

DATE OF REVISION	SUMMARY OF CHANGE
07/17/2024	Policy creation
01/15/2025	Removed prescriber specialty requirement

Review Date: 07/17/2024

Revision Date: 01/15/2025

© Copyright 2025 by The Johns Hopkins Health System Corporation and/or The Johns Hopkins University